Blog
RSS FeedPosted by Michael Wonder on 05 May 2018
Watchdog says Vertex cystic fibrosis drugs are not cost effective, but company calls analysis a ‘sham’
4 May 2018 - The oldest Vertex drug for cystic fibrosis, Kalydeco, lists for $311,000, while the newer treatment Orkambi lists ...
Posted by Michael Wonder on 05 May 2018
ICER releases draft evidence report on elagolix for endometriosis
4 May 2018 - Public comment period now open until 31 May; requests to make oral comment during public meeting also ...
Posted by Michael Wonder on 04 May 2018
ICER finds that at current prices CFTR modulators for cystic fibrosis improve patient outcomes at costs that far exceed standard cost-effectiveness levels
3 May 2018 - Evidence report findings and contextual factors related to treatments for ultra-rare disorders such as cystic fibrosis ...
Posted by Michael Wonder on 27 Apr 2018
ICER releases draft condition update report on treatments for plaque psoriasis
27 April 2018 - Public comment period now open until 25 May; requests to make oral comment during public meeting ...
Posted by Michael Wonder on 27 Apr 2018
ICER posts draft scoping document on medication-assisted treatments for opioid use disorder
26 April 2018 - Document open to public comment until 16 May 2018; report expected to review buprenorphine implant, extended-release ...
Posted by Michael Wonder on 24 Apr 2018
Institute for Clinical and Economic Review to assess biologic treatments for asthma in upcoming assessment
24 April 2018 - Report will be subject of November Midwest CEPAC meeting; open input now being accepted until 10 ...
Posted by Michael Wonder on 16 Apr 2018
ICER's final report on emicizumab shows new treatment improves health while lowering costs for certain people with haemophilia A
16 April 2018 - Report also highlights need for future pricing of haemophilia treatments that allows for "shared savings" between innovators ...
Posted by Michael Wonder on 12 Apr 2018
ICER posts draft scoping document on therapies for prevention of hereditary angioedema attacks
12 April 2018 - Document open to public comment until 2 May 2018; report expected to review lanadelumab (Shire), and C1 ...
Posted by Michael Wonder on 12 Apr 2018
ICER releases draft evidence report on CGRP inhibitors for migraine prevention
11 April 2018 - Public comment period now open until 8 May; requests to make oral comment during public meeting also ...
Posted by Michael Wonder on 05 Apr 2018
ICER to assess medication-assisted therapy for treatment of opioid use disorder
5 April 2018 - Report will be subject of November New England CEPAC meeting; open Input now being accepted until 24 ...
Posted by Michael Wonder on 30 Mar 2018
ICER announces new program to make available draft executable economic models during drug assessment review process
30 March 2018 - Pilot program will allow more extensive evaluation of draft economic models used in ICER's reports. ...
Posted by Michael Wonder on 18 Mar 2018
Policy strategies for aligning price and value for brand-name pharmaceuticals
15 March 2018 - Systemic factors in the US health care system lead to greater pricing power for drug manufacturers than ...
Posted by Michael Wonder on 16 Mar 2018
ICER releases draft evidence report on CFTR modulator therapies for cystic fibrosis
15 March 2018 - Public comment period now open until 12 April; requests to make oral comment during public meeting also ...
Posted by Michael Wonder on 15 Mar 2018
ICER finds emicizumab reduces treatment cost while improving health of people with haemophilia A
15 March 2018 - Report will be subject to public deliberation during New England CEPAC meeting on 29 March 2018. ...
Posted by Michael Wonder on 13 Mar 2018
America’s “NICE”?
12 March 2018 - “The health of a democratic society may be measured by the quality of functions performed by ...